Radiopharm Theranostics - ADR opened lower at $0.80, compared with its previous close of $0.82. In the last trading session, the stock traded between $0.74 and $0.80. It showed a downward intraday trend.
An investment of $100 made 2 years ago in Radiopharm Theranostics - ADR is now worth
$ 4.45
Resulting in a loss of
$ 95.55 (95.55%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.03 (-4.15%)
Day High
$0.80
Day Low
$0.74
Day Open
$0.80
Prev Close
$0.82
Volume
32,144
1W Return
-6.87%
1M Return
-31.95%
3M Return
-71.96%
6M Return
-80.35%
1Y Return
-82.88%
Market Cap ($ Mn)
12
PE Ratio
-
PB Ratio
1.10
PEG Ratio
-
ROE
-91.21%
ROCE
-57.08%
EPS (TTM)
-
1 Week
-6.87%
1 Month
-31.95%
3 Months
-71.96%
6 Months
-80.35%
9 Months
-84.50%
Radiopharm Theranostics completes FDA EOP2 meeting for RAD101
Completed End-of-Phase 2 (EOP2) meeting with FDA for RAD101. RAD101 showed **93% concordance** with MRI in Phase 2b trial. FDA meeting minutes expected within approximately 30 days. Company executing Phase 3 readiness activities ahead of feedback.
1mo agoRadiopharm doses first patient in second cohort of RV-01 Phase 1/2a trial
Radiopharm Theranostics dosed the first patient in the second cohort of its Phase 1/2a trial for RV-01. The Safety and Monitoring Committee recommended advancing to the 70 mCi dose level. RV-01 targets B7-H3 expressing solid tumors using a 177Lutetium-tagged monoclonal antibody. The trial aims to enroll 61 participants across various cancer types including prostate and lung cancers.
2mo agoRadiopharm advances RAD202 trial to 180mCi dose level in Phase 1 HEAT study
Radiopharm Theranostics advances its Phase 1 HEAT trial for 177Lu-RAD202 to Cohort 4, increasing the dose to 180mCi from 130mCi. The DSMC cited favorable safety profiles in HER2-positive advanced solid tumor patients. This follows earlier proof-of-concept data in breast cancer diagnostics.
2mo agoRadiopharm Theranostics Q2 Results: Cash falls to $4.1M as RAD 101 hits endpoint
Radiopharm Theranostics reported Q2FY26 results with closing cash dropping to $4.1M from $19.2M due to $14.97M in operating outflows. Key clinical news includes RAD 101 meeting its primary endpoint in Phase 2b trials with 93% concordance. Post-quarter, the company raised $12.5M via an institutional offer and launched a $6M Share Purchase Plan.
3mo agoRadiopharm reports durable partial response in RAD204 trial
Radiopharm Theranostics announced updated clinical results from the Phase 1 trial of RAD204, showing a confirmed durable Partial Response in a patient at the 90 mCi dose level with a 43% reduction in target lesions. A second patient showed early tumor shrinkage and remains progression-free. RAD204 was generally well-tolerated with no dose-limiting toxicities observed across dosing cohorts.
3mo agoRAD101 PET shows 93% concordance with MRI in Phase 2B trial
Radiopharm Theranostics reported 93% concordance with MRI in its Phase 2B trial of RAD101 for suspected brain metastases recurrence. Preliminary analysis indicated 86% sensitivity. The company targets a $600 million market and plans a Phase 3 trial in Q4 2026.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 2 years ago in Radiopharm Theranostics - ADR is now worth
$ 4.45
Resulting in a loss of
$ 95.55 (95.55%)
Note: Past profits do not guarantee future returns.
